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Upper and lower airways may be considered as a unique entity, interested by coexisting inflammatory 
processes that share common etiopathogenic mechanisms. Previous studies have strongly demonstrated 
a relationship between rhinosinusitis and asthma. This has led to the introduction of the concept of 
“united airways”, which has also been included in the WHO document Allergic Rhinitis and its Impact 
on Asthma (ARIA); this concept has important consequences also on the treatment of these disorders. 
To better summarize the evident connection between upper and lower airway disease we decided to 
describe it as a multilayered construction, each level pointing out more deeply the relationship between 
these entities.
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Upper and lower airways may be considered 
as a unique entity, interested by coexisting 
inflammatory processes that share common 
etiopathogenic mechanisms. Epidemiological, 
clinical and pathophysiological studies have 
strongly demonstrated a relationship between airway 
disorders, namely rhinosinusitis and asthma (1). This 
has led to the introduction of the concept of “united 
airways”, also known as “one airway, one disease”, 
which has also been included in the WHO document 
Allergic Rhinitis and its Impact on Asthma (ARIA) 
(2). According to this model, allergic rhinitis and 
asthma are one syndrome, expressed in two different 
parts of the respiratory tract; furthermore, allergic 
inflammation is associated with an increased 
likelihood of developing rhinosinusitis (3, 4).
This concept has important consequences on the 
treatment of these disorders (5, 6). Asthma must be 
treated considering its various triggers and possibly 
eliminating them. Consequently, after a diagnosis 
of asthma, a screening for upper airway diseases 
should be contemplated (5). Similarly, patients with 
rhinosinusitis should be evaluated for a possible 
concomitant asthma (6). To better summarize the 
evident connection between upper and lower airway 
disease we decided to describe it as a multilayered 
construction, each level pointing out more deeply the 
relationship between these entities.
EPIDEMIOLOGIC LEVEL
Epidemiology can highlight associations and 
cause-effect relationships between rhinosinusitis 
and asthma. Many studies have strongly shown the 
co-existence of rhinitis and asthma (1, 3, 7). Most 
patients with asthma also have rhinitis, whereas 
there is an increased risk of asthma in subjects with 
allergic rhinitis and to a lesser extent non-allergic 
rhinitis (4). In particular, epidemiological data 
suggest that up to 80% asthma patients also suffer 
from allergic rhinitis, and up to 40% of patients with 
rhinitis also have asthma (3). Allergic rhinitis often 
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common diseases that frequently coexist. There are 
not many studies on the comorbidity of asthma and 
chronic rhinosinusitis. While the epidemiological 
association between chronic rhinosinusitis and 
asthma has been clearly established, the exact 
pathophysiologic mechanism remains controversial 
(14). A recent Global Allergy and Asthma Network 
of Excellence (GA2LEN) survey (15) demonstrated 
a strong association of asthma with chronic 
rhinosinusitis. The relationship was greater in 
subjects with both chronic rhinosinusitis and allergic 
rhinitis, while chronic rhinosinusitis without nasal 
allergy was associated with late-onset asthma (15). 
It has been estimated that 20–33% of patients with 
chronic rhinosinusitis also have asthma, a prevalence 
nearly four times greater than that of the general 
population (15). On the other hand, 85% to 90% of 
patients with asthma have abnormal findings on CT 
scans of the sinuses (16). A recent Swedish survey 
showed that 63.9% of subjects with physician-
diagnosed asthma had allergic rhinitis, 39.8% had 
chronic rhinitis and 8.4% had chronic rhinosinusitis 
(17). On the other hand, prevalence of physician-
diagnosed asthma was 19.8% in allergic rhinitis, 
16.5% in chronic rhinitis and 24.4% in chronic 
rhinosinusitis (17). Prevalence of asthma increased 
with the number of nasal conditions in the patient, 
including allergic rhinitis, nasal congestion and nose 
dripping; similarly, chronic rhinosinusitis was ten-
fold more common in subjects with four symptoms 
of asthma than among subjects without asthmatic 
symptoms. These numbers are in agreement with the 
findings of a large European multicenter study (7), 
which demonstrated comorbid rhinitis in 50-77% 
of subjects with asthma and asthma in 8-23% of 
patients with rhinitis and with the results of a Belgian 
study (18), which found a prevalence of asthma 
of 24% of subjects  with chronic rhinosinusitis. 
In the same Belgian study, 36% of patients with 
chronic rhinosinusitis had bronchial hyperreactivity 
(18). Other studies found even higher incidence 
of bronchial hyperresponsiveness after bronchial 
provocation test, up to 71% of subjects with chronic 
rhinosinusitis in the study of Okayama et al. (19). 
Several works have found a relationship between the 
severity of sinonasal pathology and that of asthma 
(1, 11, 20). A Dutch study including 89 patients 
with severe asthma demonstrated anomalies of CT 
precedes the development of asthma in children, and 
this sequence is commonly called the atopic march. 
Large studies have found a link between the severity 
and/or control of both diseases in children and 
adults; in particular, poor asthma control is linked to 
moderate-severe rhinitis, which should be identified 
and treated (5). Numerous studies have also shown 
that treatment of AR will improve asthma outcome 
(1, 5). According to some studies (8), asthma is 
more common in patients with moderate-to-severe 
persistent rhinitis; according to others, there is no 
correlation between ARIA categories of rhinitis and 
prevalence of asthma (9). Rhinitis is a significant 
and independent risk factor for asthma onset, as it 
often precedes bronchial hyperreactivity (1). AR has 
also been linked to “small airway disease”, defined 
as a reduction in forced expiratory flow (FEF) at 
25%-75% of the pulmonary volume and a normal 
spirometry, which is suggested to be an early marker 
of bronchial involvement in patients with rhinitis 
who perceive only nasal symptoms (10).  
On the contrary, the correlation between allergic 
rhinitis and the development of sinus pathology is not 
fully understood. Evidence is not enough to support 
the role of allergic rhinitis in the etiopathogenesis of 
chronic rhinosinusitis. A recent study (11) considered 
a cohort of 4,044 children with chronic rhinosinusitis 
and found a prevalence of allergic rhinitis of 27%, 
a value that falls within the range of prevalence of 
allergic rhinitis in the pediatric population, which 
has been estimated from 10 to 40% (12). Chronic 
rhinosinusitis encompasses a heterogeneous group 
of disorders that manifest themselves with chronic 
mucosal inflammation of nose and paranasal sinuses. 
Sinus inflammation has a multifactorial aetiology in 
which not only allergic inflammation, but also other 
factors are involved (4). IgE-mediated inflammation 
of nasal mucosa determines nasal congestion, leading 
to impaired drainage of mucus at the ostiomeatal 
complex (6). Stagnation of secretions, decreased 
ventilation, mucosal inflammation and decreased 
mucociliary transport all contribute to facilitate 
bacterial infection (6). Besides, recent works have 
shown that nasal challenge with allergen causes also 
secondary maxillary sinus inflammatory response in 
addition to nasal inflammatory changes (13). These 
findings might help explain the close relationship 
between allergic rhinitis and rhinosinusitis, two very 
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with more severe asthmatic symptoms in patients 
with poorly controlled asthma at baseline (24); 
furthermore, rhinosinusitis (but not allergic rhinitis) 
was associated with more asthmatic exacerbations 
(24). In the same study, rhinosinusitis was also 
associated with worse asthma-related quality of life 
and more sleep disturbance (24). Globally, many 
recent works confirm the strong co-occurrence of 
chronic rhinosinusitis and asthma, suggesting a 
partially common etiopathogenesis. 
ANATOMIC LEVEL
Upper and lower airways are linked both 
macroscopically and microscopically. The airways 
are a continuous pathway extending from nose and 
paranasal sinuses to pulmonary alveoli. The nose 
holds a pivotal position at the entry of the airways 
and contributes in protecting the following tract 
by humidifying, heating and filtering the inspired 
air. Nasal breathing provides a protective influence 
against the onset of exercise-induced asthma, 
whereas oral breathing is more likely to exacerbate 
symptoms (25). Mouth breathing allows inhaled gas 
to by-pass the conditioning processes of the nasal 
mucosa. As a result, increased concentrations of 
inhaled aeroallergens may reach the lower airways 
accompanied by increased drying and cooling of 
bronchial mucosal surfaces. Thus, inhaling cold, dry 
air at high ventilatory levels via the mouth, as occurs 
during exercise, can initiate a bronchoconstrictive 
response in some asthmatic subjects (25). Also 
nasal pathology leads to the interruption of nasal 
breathing and, consequently, of nasal shielding 
function, becoming a potential trigger for bronchial 
disorders (3). Besides, nasal sinuses become 
sources of inflammatory discharge, dripping in 
the lower airways. There are similarities between 
mucous membranes covering upper and lower 
airways. They are constantly exposed to the external 
environment, therefore they act as the first line of 
defense against microorganisms and atmospheric 
particulate matter. Both nose and bronchi are lined 
with a pseudostratified respiratory epithelium made 
up of columnar ciliated cells. The epithelium has an 
important barrier function and the loss of its integrity 
can cause major penetration of microorganisms and 
antigens, compromising the interaction between the 
scans in 84% of patients and extensive sinus disease 
in 24% of patients (21). Besides, there was a direct 
relationship between the extent of sinus disease, 
measured as thickness of sinonasal mucosa on CT 
scan and bronchial inflammation, reflected both by 
the presence of eosinophils in bronchi and blood and 
by the level of nitric oxide in exhaled air (21). Another 
study found that sinonasal pathology, as assessed by 
clinical symptoms and CT scan, was significantly 
worse in subjects with severe steroid-dependent 
asthma than in those with mild-to-moderate asthma, 
although global frequency of rhinosinusitis was 
similar in the two groups (16). Similarly, a more recent 
study showed that increasing severity of asthma 
was associated with greater radiological severity 
of chronic rhinosinusitis (evaluated on CT scan 
using Lund-Mackay score) and a higher prevalence 
of allergic sensitization and nasal polyposis (22). 
Interestingly, when the study population was stratified 
by the presence of polyps, there was no difference 
in radiological severity of chronic rhinosinusitis 
between asthmatic and non-asthmatic patients; 
this suggested that increasing radiological severity 
associated with worse asthma was attributable to the 
greater presence of nasal polyps (22). Furthermore, 
the study highlighted the potential role of allergic 
sensitization and nasal polyps as additional factors 
in disease pathogenesis (22). Asthma and chronic 
rhinosinusitis with nasal polyposis often co-exist, 
but their relationship is still unclear. A recent work 
demonstrated a high prevalence of asymptomatic 
lower airway dysfunction in subjects with chronic 
rhinosinusitis with nasal polyposis (23); alongside 
asthmatic individuals, in fact, many patients had a 
marked elevation of FeNO and/or asymptomatic 
bronchial hyperreactivity, an impairment of lower 
airways suggestive of an asthmatic phenotype 
without clinical asthma (23). The aforementioned 
Swedish survey found that asthma subjects with 
chronic rhinosinusitis more lower respiratory 
symptoms than those with allergic rhinitis as well 
as those without nasal comorbidities, suggesting 
that the degree of nasal pathology may be markers 
of different asthma phenotypes (17). Two clinical 
trials conducted by the American Lung Association-
Asthma Clinical Research Centers (ALAACRC) 
enrolling asthmatic subjects showed that both 




Nose and bronchi seem to communicate through a 
neural reflex pathway. The nasobronchial reflex, 
first described in the late 1960s, consists of 
bronchoconstriction and increase in pulmonary 
resistance following exposure of the nose to cold 
air or irritants (27). Different studies show that 
allergen deposition in either nose or bronchi leads to 
inflammatory changes in a distant site of the airways 
(30). Consequently, nasal allergen provocation can 
cause bronchial hyperresponsiveness. The efferent 
pathway of nasobronchial reflex seems to be due 
to the activation of the NANC system. The NANC 
nerves are essentially sensory, but axon reflexes 
determined by antidromic stimulation of nerve fibers 
can lead to the release of inflammatory neuropeptides, 
and particularly substance P, by pulmonary nerves, a 
phenomenon called neurogenic inflammation (31).
IMMUNOLOGIC LEVEL
Evidence in recent literature demonstrates 
a systemic and not only anatomical connection 
between upper and lower airways (3). Inflammatory 
diseases of the upper airways, such as allergic rhinitis 
and chronic rhinosinusitis, determine a systemic 
immune response, with elevated levels of IL-5 in 
blood and increased bone marrow eosinopoiesis. 
Besides, nasal allergen provocation determines a 
raise in blood IL-5, bone marrow eosinopoiesis and 
blood eosinophilia (32). Inflammatory mediators are 
released from upper airways into the bloodstream; 
moreover, allergens are systemically absorbed 
through nasal mucosa and they could determine 
systemic activation of immune cells (32). Respiratory 
chronic inflammatory diseases, including asthma, 
allergic rhinitis and chronic rhinosinusitis, share 
several common features. Allergic inflammation is 
characterized by IgE-dependent mast cell activation 
and degranulation and by infiltration of eosinophils, 
determined by activated CD4+ Th2 lymphocytes 
(33). The simple paradigm of non-overlapping 
stable Th1 and Th2 subsets of T-helper cells is now 
rapidly being replaced by that of a more complex 
spectrum of different Th cells that together drive or 
control different aspects of allergic inflammation 
and display more plasticity in their cytokine profiles. 
At present, these include Th9, Th17, Th22, and Treg, in 
addition to Th1 and Th2 (33). 
host and environmental antigens and predisposing to 
inflammation (4). Dysfunctions of epithelial barrier 
can be due to both congenital and acquired factors. 
Multiple defects in the expression of different 
epithelially-derived genes could lead to defective 
barrier function in patients with chronic rhinosinusitis 
(26). The main constituents of the epithelial barrier 
are intercellular tight junctions, which have been 
demonstrated being altered in both asthma and 
chronic rhinosinusitis with nasal polyps (26, 27). 
A possible role of proinflammatory cytokines has 
been suggested by the observation of the disruption 
of epithelial integrity of the sinonasal mucosa by 
IFN-γ and IL-4 in vitro (26). There are also many 
environmental factors that can compromise epithelial 
barrier. For example, rhinovirus infection can 
disrupt airway epithelial barrier function, facilitating 
secondary bacterial infection and this effect is 
independent from proinflammatory cytokines (28). 
Besides, it was observed that synthetic double-
stranded RNA (dsRNA), which reproduced viral 
dsRNA, could induce disruption of airway epithelial 
apical junctional complexes via a TLR-3 pathway 
(28). The greater penetration of inhaled allergens into 
the subepithelial space could explain the association 
between viral respiratory tract infections, airway 
inflammation and allergic sensitization. Similarly, 
it is known that the allergen Der p 1 of house dust 
mite Dermatophagoides pteronyssinus is a cysteine 
proteinase with proteolytic activity that can open 
epithelial tight junctions (29). Other substances, 
such as ozone, tobacco smoke, chlorination products 
and endotoxins are also able to break tight junctions 
and favor allergic sensitization (27). The airway 
submucosa is rich in vessels, mucous glands, 
connective tissue, immune system cells and nerves. 
Vascularization is richer in nasal mucosa, explaining 
the higher possible obstruction, while smooth 
muscle starts in the trachea and allows bronchial 
constriction (4). The nervous system plays a key role 
both in physiologic and in pathologic settings. The 
autonomic nervous system of airway submucosa 
includes adrenergic, cholinergic and non-adrenergic 
noncholinergic (NANC) nerves. Adrenergic control 
of nose and bronchi differs, since α-adrenergic 
agonists are nasal vasoconstrictors, while ß2-
adrenergic agonists are bronchodilators; on the 
contrary, cholinergic nerves are bronchoconstrictors. 
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with chronic rhinosinusitis, finding a relationship 
between the predominance of eosinophils in nasal 
secretions and asthma comorbidity. Therefore, there 
might exist an effect of upper airway eosinophils 
over the lower airways. The preponderance of 
activated eosinophils in an inflammatory infiltrate is 
associated with major basic protein (MBP) release, 
epithelial destruction and denudation of basement 
membrane. The propagation of eosinophil toxic 
inflammatory products, such as MBP, to the lower 
airways, both through the bronchi and through 
systemic circulation might aggravate inflammation 
of the lower airways (39). The levels of eosinophil 
products, like MBP, are raised both in asthma 
(33) and in chronic rhinosinusitis (39). In subjects 
without allergic diseases chronic rhinosinusitis 
is associated with non-allergic asthma, in which 
superantigens seem to play a major role (40). 
These are proteins derived from different sources, 
including bacteria, viruses and human hepatic tissue 
and they are able not only to induce polyclonal 
activation of T lymphocytes, but also to act broadly 
on the immune system, affecting B lymphocytes, 
mast cells, basophils, and chemokine production. 
Superantigens might also have a superallergen 
action, activating mast cells and basophils and 
determining a Th2 pattern of inflammation, with 
class-switching of immunoglobulins to IgE (40). 
A broadly studied superantigen is Staphylococcus 
aureus enterotoxin B (SEB). It was demonstrated 
that airway mucosal application of SEB is capable 
of aggravating bronchial allergic inflammation, 
increasing bronchial eosinophilia, expression of IL-
4, IL-5 and IFN-g in bronchi and blood, bronchial 
expression of eotaxin-1 and TGF-b and polyclonal 
IgE levels (40). One study found that these polyclonal 
IgE antibodies, whose formation in nasal polyps is 
induced by Staphylococcus aureus, are functional 
and able to activate mast cells, contributing to chronic 
inflammation (40). Besides, IgE in nasal polyp 
tissue can be found independently of their presence 
in serum. In patients with chronic rhinosinusitis the 
rate of Staphylococcus aureus carriage observed at 
the middle meatus was approximately 35% (40). 
In subjects with nasal polyposis, on the other hand, 
specific IgE directed against Staphylococcus aureus 
enterotoxins could be found in nearly 50% of nasal 
polyp tissue samples (40). These samples were 
The analysis of upper and lower airway biopsies 
of individuals suffering from both asthma and 
allergic rhinitis showed a parallel inflammatory 
response, with similar numbers of inflammatory cells 
and possible bidirectional extension of inflammation 
between the nose and bronchi (34). Hypothetically, 
different activation states of inflammatory cells 
could be responsible for the different clinical 
manifestations. Moreover, in non-asthmatic subjects 
with allergic rhinitis there is an inflammatory response 
in lower airways, which is intermediate between 
that observed in normal individuals and asthmatics 
and is characterized by the presence of submucosal 
eosinophils and mast cells (32). On the other hand, an 
eosinophil infiltration was demonstrated in the nasal 
mucosa of asthmatic individuals in the absence of 
allergic rhinitis (35). There is a remarkable overlap 
between histopathological characteristics of chronic 
rhinosinusitis and asthma, particularly eosinophilic 
inflammation and features of airway remodeling, 
such as shedding of the epithelium and basement 
membrane thickening (35). The fraction of exhaled 
nitric oxide (FeNO) has been widely used as a marker 
of airway inflammation in asthma in recent years. 
The measure of FeNO has also been used to show 
the presence of lower airway inflammation in rhinitic 
patients, with or without asthma (36). It has been 
demonstrated that forced expiratory flow between 25 
and 75 percent of vital capacity (FEF25-75) is strongly 
and inversely related with FeNO, and FEF25-75 may 
predict high FeNO levels in children with allergic 
rhinitis, asthma or both (36, 37). Furthermore, 
FeNO is also strongly related with the response to 
bronchodilation testing and could predict bronchial 
reversibility in children with allergic rhinitis or 
asthma (38).
Therefore, these airway inflammatory diseases 
might be different site-specific manifestations of 
the same disorder. Different classes of leukocytes 
are involved in the persistent inflammation of the 
nasal mucosa, including eosinophils, whose number 
is increased in biopsies of subjects with chronic 
rhinosinusitis, alongside the levels of GM-CSF, 
IL-3 and IL-5, in comparison to control tissue (33). 
Besides, a higher involvement of eosinophils has 
been demonstrated when chronic rhinosinusitis is 
associated with asthma (39). One study (39) analyzed 




Moreover, Th17 cells may promote both eosinophilic 
and neutrophilic inflammation in allergic rhinitis and 
chronic rhinosinusitis (43). 
Despite these recent findings, further studies are 
needed to further define the role of Th17-cytokines in 
regulating allergic airway inflammation.  
GENETIC LEVEL
Allergic diseases, allergic rhinitis and asthma 
included, usually recur inside families, proving an 
underlying hereditary component. Nevertheless, 
the increase in the prevalence of these disorders has 
occurred in only a few decades, a time lapse too 
short for major changes in the genetic patrimony 
of the population. Therefore, environment and 
lifestyle modifications had an undeniable role in 
this epidemiological change. Several studies have 
led to the identification of genes possibly involved 
in development of IgE-mediated immune responses, 
sensitization to allergens or clinical manifestations 
of allergy (44). There are only a few genome-wide 
association studies concerning rhinitis, and they all 
seem to point to the importance of genes implicated in 
immunoregulation, Th2 response and innate immunity. 
A recent genome-wide association meta-analysis 
identified only a few loci that associated with the 
risk of allergic rhinitis and grass pollen sensitization. 
The HLA variant rs7775228 was strongly associated 
with grass sensitization and weakly with allergic 
rhinitis; various loci in the HLA region have been 
implicated in candidate gene studies of asthma or 
allergic disorders (44). Polymorphism in the 11q13.5 
locus was associated with both allergic rhinitis and 
IgE sensitization to grass; this locus is located near 
leucine-rich repeat containing 32 (LRRC32), a 
molecule which is critical for tethering TGF-beta to 
the cell surface on activated Tregs (45). The role of 
TGF-beta on Tregs appears to have dual functions, 
both Treg-mediated suppression and infectious 
tolerance mechanism. The third variant found was 
rs17513503, situated at 5q22. Furthermore, using a 
candidate gene approach the same study identified 
three genes of possible interest, thymic stromal 
lymphopoietin (TSLP), Toll-like receptor 6 (TLR6) 
and nucleotide-binding oligomerization domain 
containing 1 (NOD1/CARD4) (45). Concerning 
chronic rhinosinusitis, a hereditary basis has been 
characterized by severe eosinophilic inflammation, 
demonstrated by the increase of IL-5, eotaxin, 
eosinophil-cationic protein (ECP) and cysteinyl-
leukotriene synthesis. Furthermore, many of these 
individual had comorbid asthma and hypersensitivity 
to aspirin. A meta-analysis has shown that asthmatic 
patients were more likely than controls to have serum 
specific IgE to Staphylococcus aureus enterotoxins; 
on the other hand, the probability of a positive test 
for local or systemic exposure to Staphylococcus 
aureus and/or or its enterotoxins was higher in 
subjects with allergic rhinitis (40). Moreover, it 
was demonstrated that Staphylococcal enterotoxin 
IgE are risk factors for asthma severity (40). 
Consequently, Staphylococcus aureus superantigens 
may have a role in the onset and severity of allergic 
diseases, namely asthma and allergic rhinitis. Not 
only bacteria, but also fungi, especially Alternaria, 
may play a role in the generation of chronic 
rhinosinusitis (41). Cytokines produced by tissue-
bound lymphocytes recruit eosinophils, which attack 
fungi, recognized as strangers by the immune system 
of patients with chronic rhinosinusitis. Hence, there 
might be a comorbid IgE-mediated hypersensitivity 
to molds, but eosinophilic inflammation seems to be 
driven by a non-IgE-mediated mechanism. Besides, 
Alternaria is able to induce eosinophil degranulation 
(41). Therefore, innate eosinophilic response to 
certain environmental fungi may be important in 
the onset of inflammatory airways diseases, such as 
asthma and chronic rhinosinusitis.
As mentioned before, the classic paradigm of 
Th1/Th2 cell-mediated immunity recently evolved to 
include a novel Th cell subset expressing IL-17, named 
as Th17 cell, which appears to be involved in a number 
of immune-mediated diseases, including asthma, and 
also allergic rhinitis and chronic rhinosinusitis (42). 
In particular, moderate and severe asthma phenotypes 
have been associated with increased neutrophils and 
increased Th17 cytokines, IL-17A, IL-17F, and IL-
22, in the bronchoalveolar lavage fluid of patients 
(42). IL-17A has also been shown to be elevated 
in the sputum of patients with severe asthma and 
the levels correlated with neutrophil chemokines 
such as IL-8 as well as neutrophil numbers (42). 
In addition, Th17 cytokines also induce mucous cell 
metaplasia and have pleotropic effects on airway 
smooth muscle resulting in airway narrowing (42). 
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inflammation (2, 5). Immunotherapy, besides 
reducing symptoms of allergic rhinitis, is effective in 
mild asthma and can even prevent the development 
of asthma and exacerbations and to improve quality 
of life in individuals with both asthma and persistent 
allergic rhinitis (2, 5). Recent reports have suggested 
a possible clinical use of omalizumab, a human 
anti-IgE monoclonal antibody, in allergic rhinitis 
and chronic rhinosinusitis with nasal polyps (47). 
In a recent randomized, double-blind, placebo-
controlled trial, Gevaert et al. reported a significant 
reduction in total nasal endoscopic polyp scores 
with the use of Omalizumab for the management of 
allergic and non-allergic patients with nasal polyps 
and asthma (47). Moreover, a recent meta-analysis 
of randomized clinical trials assessed the efficacy 
and safety of omalizumab in patients with poorly 
controlled AR (48).
However, both medical and surgical treatment 
of chronic rhinosinusitis were associated with 
improvements in asthma (49, 50). Endoscopic 
sinus surgery (ESS) for chronic rhinosinusitis 
in subjects with concomitant bronchial asthma 
reduces frequency of asthma attacks, number of 
hospitalizations and medication use and improves 
asthmatic symptoms, but apparently not lung 
function testing (49). One work demonstrated that 
the combination of ESS and medical postoperative 
therapy had a favorable long-term effect on asthma 
in patients with chronic rhinosinusitis. Asthma was 
better than it had been before the ESS for 90% of 
patients after a mean follow-up period of 6.5 years 
(49). In patients with nasal polyposis and comorbid 
asthma, a significant improvement in lung function 
and asthmatic symptoms and a reduction in the use 
of systemic corticosteroid were demonstrated after 
ESS, but not in subjects with aspirin-intolerant 
asthma (50).
CONCLUSIONS
Rhinosinusitis and asthma are two conditions 
frequently encountered, representing a range of 
overlapping diseases with a similar pathophysiological 
mechanism, where environmental stimuli, 
immunological predsposition, chronic airway 
mucosal inflammation and remodeling play a critical 
and integrating role in these diseases. Although 
suggested by the development of this condition in 
certain genetic disorders and by family and twin 
data. Despite that, genome-wide association studies 
are lacking at the moment and no single causative 
genes have been identified. Studies seem to implicate 
defects in innate immune response, including the 
TLR system, thus supporting the importance of 
environmental pathogens (e.g., bacteria) in the 
pathogenesis of the disease. To date, polymorphisms 
in more than 30 genes have been associated to 
chronic rhinosinusitis (46). The risk related to single 
nucleotide polymorphisms is modest, but taken as 
a group they can be important for the development 
of the disease. In conclusion, genetic determination 
of allergic disease is much more complicated than 
previously supposed, with distinct paths determining 
IgE production, sensitization, target organs and 
allergy. Besides, genetic variations are not enough 
to determine these disorders, but they can confer 
susceptibility for them. Therefore, gene-environment 
interactions are necessary in the development of 
allergic diseases.
THERAPEUTIC IMPLICATIONS
Given the strong comorbidity of airway 
inflammatory diseases, specifically allergic rhinitis, 
chronic rhinosinusitis and asthma and the trend to 
a synergic effect of these disorders, which tend to 
worsen one another, a global strategy of treatment 
is necessary to fully control their manifestations and 
consequences. The unified airway model, given the 
influences of pathological processes of upper airways 
on the lower airway, has led to therapies directed at both 
targets. The treatment of allergic rhinitis may provide 
a better control of comorbid asthma. Particularly, the 
use of nasal corticosteroids in subjects with allergic 
rhinitis has been demonstrated to reduce bronchial 
hyperresponsiveness, asthma-related symptoms and 
visits to emergency departments related to asthma 
(2, 5). Second- and third-generation antihistamines, 
besides being very effective in the treatment of 
allergic rhinitis, might have a role in treating mild-
to-moderate asthma, at doses greater than those 
used for allergic rhinitis (2, 5). Leukotriene receptor 
antagonists, and specifically montelukast, are 
effective in the treatment of both allergic rhinitis 
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